Participating in a clinical trial is a personal decision, and making that decision will look different for everyone. As a caregiver, you are among the …
Our Perspectives, Ideas & Research on Drug Discovery | Gain Therapeutics
Advancing GBA1 Research: A Glimpse into GBA1 Canada’s Mission and Impact GBA1 Canada (G-Can) stands at the forefront of neurodegenerative disease research, focusing on the …
Clinical trials are the engine of medical innovation. Every approved treatment or therapy on the market today began its life in a lab and went …
Mitochondria and the Electron Transport Chain Mitochondria are organelles within eukaryotic cells, and are responsible for generating energy. This energy is in the form of …
On April 26, 2025, thousands gathered in New York City’s Central Park for the 31st annual Parkinson’s Unity Walk, a cornerstone event hosted by The …
The right self-care practices can make patients and caregivers confident about making it through the journey when diagnosed with Parkinson’s disease. Self-care, from finding hobbies …
Gain Therapeutics shared important updates at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases. The company presented new preclinical data as well as …
April is Parkinson’s Awareness Month, a time to raise awareness about Parkinson’s disease (PD), support those living with it, and contribute to vital research for …
The world’s leading experts in neurodegenerative diseases gather at the AD/PD Conference (Alzheimer’s Disease and Parkinson’s Disease) to present groundbreaking research, share insights, and discuss …
What is the UPDRS? The Unified Parkinson’s Disease Rating Scale, or UPDRS, is an assessment tool designed to assist clinicians and researchers in evaluating the …
Parkinson’s disease is a movement disorder of the nervous system that affects millions worldwide, and as researchers continue to unravel its intricacies, the future looks …
How are human clinical trials conducted? Before human trials even begin, animal trials are conducted first to evaluate safety. Once human trials begin, they move …
This September Gain Therapeutics is attending and presenting at two conferences. H.C. Wainwright 26th Annual Global Investment Conference The H.C. Wainwright 26th Annual Global Investment …
24 Sep: Ryan Reynolds Shares His Father’s Early Parkinson’s Symptoms: Subtle Signs His Family Missed
Ryan Reynolds, the charismatic star of “Deadpool & Wolverine,” recently opened up about his father’s battle with Parkinson’s disease, shedding light on the early symptoms …
Biomarkers and their use in therapeutic development Biomarkers are specific characteristics that can be used to predict the risk of disease, identify the presence of …
Summary: At the Annual Neuro Perspectives Virtual Conference hosted June 27th, H.C. Wainwright hosted a Fireside Chat with Ram Selvaraju, a Senior Healthcare Equity Research …
Parkinson’s disease (PD) remains a significant challenge in neurodegenerative research, with the GBA1 mutation presenting a particularly aggressive form of the disease. Gain Therapeutics is …
Neurodegenerative diseases and the immune system Neurodegenerative diseases, such as Parkinson’s, Alzheimer’s, Huntington’s, and Motor Neuron diseases, are generally thought of in their capacity as …
Read the research article in full. Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disease (LSD) that arises from mutations in the gene …
The new CFO fills in the missing link When you think of a Chief Financial Officer, the first thing that comes to mind is not …
The links between Alzheimer’s, Parkinson’s, and Prion diseases At first glance, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and prion disease share many generalized features. While …
Part 3 Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer In Part 3 of our discussion with Gain’s Chief Medical Officer Jonas Hannestad, …
Part 2 Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer In Part 2 of our discussion with Gain’s Chief Medical Officer Jonas Hannestad, …
What this means for the future of Parkinson’s disease On May 23, 2024, Congress officially passed the National Plan to End Parkinson’s Act (H.R.2365/S.1064). The …
Gain Therapeutics, Inc. reports promising results from its Phase 1 trial of GT-02287, a novel therapy for GBA1 Parkinson’s disease. The study indicates the therapy is safe and well-tolerated, enhancing GCase enzyme function, which is pivotal in combating the disease’s progression.
Meet Gain Therapeutics’ New Chief Medical Officer: Dr Jonas Hannestad, MD, PhD
This blog discusses Parkinson’s Disease, highlighting its history, characteristics, and ongoing research. Initiatives like the PD GENEration study offer free genetic testing. Gain Therapeutics is developing GT-02287, a potential disease-modifying drug for GBA1-Parkinson’s, with support from prominent foundations and currently conducting clinical trials.
Explore the innovative world of Gain Therapeutics in this engaging fireside chat held by Lou Basenese and Jeb Terry at the recent Public Ventures Discovery Day event. Delve into how we are revolutionizing the treatment of neurodegenerative diseases, including Parkinson’s, with our next-generation Magellanᵀᴹ platform. Gain harnesses AI and physics-based methods to develop best-in-class small molecules for disorders with high unmet medical needs. Hear about the significant strides we’ve made from current Board Member and former Gain CEO Eric Richman. A must-watch for those interested in the intersection of biotechnology, AI, and healthcare advancements.
Analyzing data from Genome Wide Association Studies (GWAS) and drawing from the insights of the PD GENEration Study, Dr. Alcalay unveils the significance of glucocerebrosidase (GBA) mutations in Parkinson’s. Discover why GBA emerges as a prime target for therapeutic interventions, offering hope for tailored treatments and improved patient outcomes.
Professor Outeiro provides an in-depth exploration of Parkinson’s disease from the perspective of a seasoned basic scientist. Covering topics ranging from disease complexity and classification to emerging biomarkers and therapeutic strategies, he delves into the intricacies of Parkinson’s research, highlighting the challenges faced by scientists and clinicians alike.